Personalis Appoints New Chief Medical Officer
Ticker: PSNL · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1527753
| Field | Detail |
|---|---|
| Company | Personalis, Inc. (PSNL) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $13.5 m, $225.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Personalis just hired a new CMO, Dr. Jake Glisson, from Tempus. Big move for their oncology focus.
AI Summary
On August 19, 2025, Personalis, Inc. announced the appointment of Dr. John D. "Jake" Glisson as its new Chief Medical Officer. Dr. Glisson brings extensive experience in oncology and precision medicine from his previous roles, including at Tempus and Foundation Medicine.
Why It Matters
The appointment of a new CMO with a strong background in oncology and precision medicine could signal a strategic shift or renewed focus for Personalis in these critical areas of medical diagnostics.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially a CMO, can introduce uncertainty regarding future strategy and execution, though Dr. Glisson's background appears strong.
Key Players & Entities
- Personalis, Inc. (company) — The company filing the report.
- Dr. John D. "Jake" Glisson (person) — Newly appointed Chief Medical Officer.
- Tempus (company) — Previous employer of the new CMO.
- Foundation Medicine (company) — Previous employer of the new CMO.
FAQ
Who is the new Chief Medical Officer at Personalis?
Dr. John D. "Jake" Glisson has been appointed as the new Chief Medical Officer.
When was the appointment of the new CMO announced?
The earliest event reported in this filing is dated August 19, 2025, which is when the appointment would have been effective or announced.
What is Dr. Glisson's relevant experience?
Dr. Glisson has extensive experience in oncology and precision medicine, with previous roles at companies like Tempus and Foundation Medicine.
What is Personalis, Inc.'s primary business?
Personalis, Inc. operates in the Medical Laboratories sector, as indicated by its SIC code 8071.
Where is Personalis, Inc. headquartered?
Personalis, Inc. is headquartered at 6600 Dumbarton Circle, Fremont, California, 94555.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2025-08-21 17:55:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PSNL The Nasdaq
- $13.5 m — ember 30, 2025 and has a value of up to $13.5 million, subject to the receipt of sample
- $225.0 million — e VA MVP has increased to approximately $225.0 million. Forward-Looking Statements This Cu
Filing Documents
- psnl-20250819.htm (8-K) — 46KB
- 0000950170-25-110739.txt ( ) — 153KB
- psnl-20250819.xsd (EX-101.SCH) — 29KB
- psnl-20250819_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 19, 2025, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on September 30, 2025 and has a value of up to $13.5 million, subject to the receipt of samples from the VA MVP and performance of services by Personalis. The cumulative value of task orders received by Personalis under its contracts with the VA MVP has increased to approximately $225.0 million.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the timing and quantity of samples received from the VA MVP; the extent to which Personalis realizes revenue, if any, from the VA MVP contract and task orders thereunder; and the enrollment of veterans in the VA MVP study, and ongoing demand of the VA MVP for Personalis' services. These forward-looking statements are subject to risks and uncertainties, including those discussed in Personalis' filings with the Securities and Exchange Commission, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 21, 2025 Personalis, Inc. By: /s/ Stephen Moore Stephen Moore Senior Vice President, Chief Legal Officer & Corporate Secretary